The INDIGO data presentation at EULAR on June 4 is a key catalyst — full dataset and expert Q&A may clarify differentiation vs standard of care. Monitor for BLA filing timeline and potential partnership interest. SLE topline in Q4 2026 adds a second catalyst.
Price Chart
Executive Summary
Zenas BioPharma announced that the Phase 3 INDIGO trial of obexelimab in IgG4-Related Disease met its primary endpoint and all four key secondary endpoints. The trial showed a highly statistically significant 56% reduction in the risk of flare versus placebo. An oral presentation of the full safety and efficacy data is scheduled for June 4 at the EULAR 2026 Congress.
Key Facts
- Phase 3 INDIGO trial met primary endpoint with 56% reduction in flare risk (HR 0.443; p=0.0005).
- All four key secondary endpoints were met with high statistical significance.
- Obexelimab was well tolerated; fewer Grade ≥3 TEAEs (11.3% vs 23.7%) and SAEs (10.3% vs 18.6%) versus placebo.
- Topline results from Phase 2 SLE trial expected Q4 2026.
- Data to be presented at EULAR 2026 Congress on June 4, 2026.
Financial Impact
Positive read-through for a registrational Phase 3 trial in a first-line indication; potential peak sales in the hundreds of millions if approved, though no financial figures were disclosed.
Risk Factors
- IgG4-RD is an orphan disease; commercial adoption depends on pricing and payer coverage.
- Obexelimab requires a partner or Zenas to build a commercial infrastructure if approved.
- Safety signals (hypersensitivity 16.5% vs 11.3%) may draw regulatory scrutiny despite overall favorable profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297346 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Press Release | $26.71 | awaiting T+60 | — | $27.24 (+1.98%) |
Oct 13, 2026 14d ago | 8-K | $25.16 | awaiting T+60 | — | $27.24 (+8.27%) |
Sep 22, 2026 5w ago | Press Release | $33.05 | awaiting T+60 | — | $27.24 (−17.58%) |
Sep 18, 2026 5w ago | Press Release | $32.55 | awaiting T+60 | — | $27.24 (−16.31%) |
Sep 11, 2026 6w ago | S-3ASR | $31.91 | awaiting T+60 | — | $27.24 (−14.63%) |
May 28, 2026 21w ago | Press Release | $18.56 $32.29 | ▲ +73.98% | ▲ +72.24% | $27.24 (+46.77%) |
May 19, 2026 23w ago | Press Release | $17.84 $29.20 | ▲ +63.68% | ▲ +57.39% | $27.24 (+52.69%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
May 13, 2026 23w ago | 8-K | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers